Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.4731
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 133321926500.0
- FreeCF/Share 1.665
- PFCF 14.1096
- PE 16.9182
- Debt/Assets 0.2946
- DivYield 0.0725
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
Published: May 12, 2025 by: Barrons
Sentiment: Negative
Trump said he would lower the cost of medicines for Americans by between 30% and 80%.
Read More
Pfizer (NYSE:PFE) Hasn't Been This Cheap in 13 Years. Time to Buy?
Published: May 09, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Pfizer (NYSE:PFE) is one of the world's largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.
Read More
Pfizer (PFE) Just Overtook the 20-Day Moving Average
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Read More
5 Low Price-to-Sales Stocks That Deserve a Place in Your Portfolio
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.
Read More
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42% and forward dividend income reaching $2,195.04. Added to positions in Bristol-Myers Squibb, Pfizer, and BP, focusing on undervalued stocks with strong dividend yields and growth potential.
Read More
3 Ultra-High Yield Dividend Stocks to Buy This May
Published: May 07, 2025 by: 24/7 Wall Street
Sentiment: Positive
These three companies have a dividend yield higher than 5%. Not only are these solid business, but they have raised dividends for many years and offer capital appreciation.
Read More
Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025 include VICI Properties, Chevron, Canadian Natural Resources, Pfizer, Altria, CVS Health, Toronto-Dominion Bank, Comcast, Vale, and Ares Capital.
Read More
Pfizer Has Unreasonable Whiff Of The Marlboro Man
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
What makes Pfizer and Altria alike? They have trouble keeping their customers. Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to Pfizer. Pfizer, meanwhile, continues to provide life-saving treatments, while its dealmaking at least offers hope of future breakthroughs.
Read More
3 Dividend Stocks Under $100 To Buy This May
Published: May 05, 2025 by: 24/7 Wall Street
Sentiment: Neutral
With volatility taking center stage since the beginning of the year, investing in the stock market isn't as easy as it was.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Top Wide-Moat Stocks to Invest in for Long-Term Growth
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Investing in wide-moat stocks like PFE, ASML, LRCX and KO can be a strategy for long-term wealth creation due to their ability to deliver consistent returns.
Read More
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025)
Published: May 02, 2025 by: 24/7 Wall Street
Sentiment: Negative
Shares of Pfizer ( NYSE: PFE ) fell by 2.09% over the past month, compounding the stock's year-to-date troubles that have seen a slide of 9.11%.
Read More
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Top-ranked stocks Fox (FOXA), Universal Technical Institute (UTI), Pfizer (PFE), Tenet Healthcare (THC) and Newmont (NEM) are likely to beat on the bottom line in their upcoming releases.
Read More
Dividend Harvesting Portfolio Week 217: $21,700 Allocated, $2,179.74 In Projected Dividends
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Positive
Alphabet's strong earnings and $75 billion capex reaffirmation set a bullish tone for big tech, boosting market confidence and economic outlook. The Dividend Harvesting Portfolio rose 2.46%, reaching a balance of $26,353.05, with a 21.44% return on invested capital and $2,179.74 in forward dividend income. Added to positions in Starwood Property Trust, Pfizer, and started a new position in Schlumberger, focusing on undervalued stocks with strong long-term potential.
Read More
3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows
Published: May 01, 2025 by: MarketBeat
Sentiment: Positive
Investors are looking for growth beyond the technology sector, and that's putting dividend stocks back in favor. The idea is simple: When a stock's growth outlook is unclear, dividends can help boost its total return and mitigate downside risk to investors' portfolios.
Read More
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.
Published: May 01, 2025 by: The Motley Fool
Sentiment: Positive
Are you looking for more income from your portfolio? Even with bond yields still near multiyear highs, plenty of dividend stocks are worth considering.
Read More
Boost Your Portfolio With These 5 Low Price-to-Book Stocks
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.
Read More
Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul
Published: April 30, 2025 by: The Motley Fool
Sentiment: Negative
Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year. And that's after recovering recently -- it was down much more than that in early April when global tariffs were first announced.
Read More
Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
When a stock yields more than 5%, investors start to become skeptical about whether the payout is indeed safe. While it's tempting to want to believe that it can be safe and that it can be an excellent source of future dividend income, you also don't want to get burned and see that dividend get cut or suspended.
Read More
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs.
Read More
Pfizer's Q1 Update May Mark A Bottom In The Stock
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Negative
Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again.
Read More
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away
Published: April 30, 2025 by: Business Insider
Sentiment: Positive
Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US.
Read More
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
Read More
Pfizer Inc. (PFE) Q1 2025 Earnings Call Transcript
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (NYSE:PFE ) Q1 2025 Results Conference Call April 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investment Relations Officer and Senior Vice President Dr. Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Chris Boshoff - Chief Scientific Officer Aamir Malik - Chief U.S. Commercial Officer and Executive Vice President Alexandre de Germay - Executive Vice President & Chief International Commercial Officer Andrew Baum - Chief Strategy & Innovation Officer and Executive Vice President Conference Call Participants Vamil Divan - Guggenheim Evan Seigerman - BMO Capital …
Read More
Pfizer's 7% Yield Makes It Look Like a Junk Bond—But Better
Published: April 29, 2025 by: Barrons
Sentiment: Neutral
The big decline in Pfizer's share price may have a silver lining.
Read More
Stocks on the move: Pfizer and Uber
Published: April 29, 2025 by: CNBC Television
Sentiment: Negative
Pfizer's down after earnings — and Josh Brown, CEO of Ritholtz Wealth Management, is making moves. Hear why he's trimming Pfizer and what he sees in Uber!
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Dr. Albert Bourla D.V.M., Ph.D.
- Employees 81000